Idorsia Ltd
SIX:IDIA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Energizer Holdings Inc
NYSE:ENR
|
US |
|
Y
|
Yunnan Copper Co Ltd
SZSE:000878
|
CN |
Idorsia Ltd
Total Receivables
Idorsia Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Receivables
CHf42.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Total Receivables
$29.1m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Receivables
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Receivables
CHf63.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
30%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Receivables
CHf40.2m
|
CAGR 3-Years
123%
|
CAGR 5-Years
96%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Receivables
CHf1.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
Glance View
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
See Also
What is Idorsia Ltd's Total Receivables?
Total Receivables
42.3m
CHF
Based on the financial report for Dec 31, 2025, Idorsia Ltd's Total Receivables amounts to 42.3m CHF.
What is Idorsia Ltd's Total Receivables growth rate?
Total Receivables CAGR 3Y
-5%
Over the last year, the Total Receivables growth was 13%. The average annual Total Receivables growth rates for Idorsia Ltd have been -5% over the past three years .
